| Trial ID: | L0372 |
| Source ID: | IRCT20220104053626N1
|
| Associated Drug: |
Rifaximin
|
| Title: |
Effect of Probiotics on elastographic findings of patients with nonalcoholic fatty liver disease
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Patients with non-alcoholic fatty liver disease diagnosed with ultrasound findings. <br>Fatty (change of) liver, not elsewhere classified;K76.0
|
| Interventions: |
Intervention 1: Intervention group: In addition to their usual medications, Rifaximin 550 mg tablets will be given twice a day for a week after one week of probiotics containing a combination of Lactobacillus rhamnosus, Bifidobacterium lactis, Lactobacill
|
| Outcome Measures: |
Determination of the effect of probiotics on hepatic steatosis in patients with non-alcoholic fatty liver disease in comparison with the control group. Timepoint: After completing 6 months of treatment, patients will undergo elastography again and the degree of stasis will be determined based on LSM and CAP criteria. Pre- and post-intervention findings will be compared. Method of measurement: After treatment, patients will undergo elastography again and the degree of stasis will be determined based on LSM and CAP criteria. Pre- and post-intervention findings will be compared.;Determination of the effect of probiotics on hepatic fibrosis in patients with non-alcoholic fatty liver disease in comparison with the control group. Timepoint: After completing 6 months of treatment, patients undergo elastography again and the degree of their liver fibrosis will be determined based on LSM and CAP criteria. The findings before and after the intervention will be compared. Method of measurement: After completing the treatment, the patients will undergo elastography again and their degree of liver fibrosis will be determined according to LSM and CAP criteria. The findings before and after the intervention will be compared.nan
|
| Sponsor/Collaborators: |
Tabriz University of Medical Sciences
|
| Gender: |
All
|
| Age: |
18 years59 years
|
| Phases: |
Phase 1/Phase 2
|
| Enrollment: |
70
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: From the patients who volunteered to participate in the study, 70 persons will be selected by simple random sampling.
|
| Start Date: |
11/01/2022
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
7 February 2022
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/61156
|
